Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 321 - 328 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC2143 | Olmesartan medoxomil |
|
Prodrug metabolised <em>in vivo</em> to Olmesartan, a selective non-peptide angiotensin II type I receptor (AT<sub>1</sub>) antagonist. Selectively inhibits angiotensin II binding to AT<sub>1</sub> receptors in bovine adrenal cortical membranes (IC<sub>50</sub> = 7.7 nM), with no effect on AT<sub>2</sub> receptors.
|
|
| BCC2145 | Vorinostat (SAHA, MK0683) |
|
Inhibits Class I and II histone deacetylases (HDACs); induces accumulation of acetylated histones H2A, H2B, H3 and H4 in transformed cultured cells. Suppresses cell growth in a range of cancer cell lines; induces apoptosis in cutaneous T cell lymphoma cells in vitro. Activates autophagy.
|
|
| BCC2148 | PCI-34051 |
|
Potent and selective histone deacetylase 8 (HDAC8) inhibitor (IC50 = 10 nM). Displays >200 fold selectivity over HDAC isoforms 1, 2, 3, 6 and 10. Induces apoptosis in cell lines derived from T cell lymphomas or leukemias.
|
|
| BCC2151 | MC1568 |
|
Selective inhibitor of class IIa histone deacetylases (HDACs). Exhibits tissue-selective inhibition between members of class II deacetylases in vivo; inhibits HDAC4 and HDAC5 in skeletal muscle and the heart without affecting HDAC3 activity. Arrests myogenesis through the stabilization of myocyte enhancer factor 2D (MEF2D)-HDAC3/4 complex. Displays no inhibition of class I HDAC activity or expression.
|
|
| BCC2156 | Valproic acid sodium salt (Sodium valproate) |
|
Histone deacetylase inhibitor (IC<sub>50</sub> = 400 <span class='symbol'>μ</span>M) that exhibits anticancer, anti-inflammatory and neuroprotective effects. Displays anticonvulsive activity via an increase in GABA levels and decreases A<span class='symbol'>β</span> production in animal models of Alzheimer's disease. Also attenuates NMDA-mediated excitation, blocks voltage-gated Na<sup>+</sup> channels and modulates firing of neurons. Enables induction of pluripotent stem cells from somatic cells by Oct4 and Sox2. Can induce autophagy by inhibiting inositol synthesis.
|
|
| BCC2162 | M344 |
|
Histone deacetylase inhibitor (IC50 = 100 nM). Induces terminal cell differentiation and causes an increase in hyperacetylated histone H4. Antiproliferative agent; suppresses the growth of human endometrial and ovarian cancer cells by inducing cell cycle arrest and apoptosis.
|
|
| BCC2163 | Scriptaid |
|
Novel histone deacetylase inhibitor. Produces > 100-fold increase in histone acetylation and displays relatively low toxicity.
|
|
| BCC2164 | Sodium Phenylbutyrate |
|
Histone deacetylase inhibitor that displays anticancer activity. Inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. Also inhibits protein isoprenylation, depletes plasma glutamine, increases production of fetal hemoglobin through transcriptional activation of the <span class='symbol'>γ</span>-globin gene and affects hPPAR<span class='symbol'>γ</span> activation.
|
|